Clinical trialNCT06033196RecruitingPhase 2Interventional

Tocilizumab in Lung Transplantation

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment350Lung Transplant

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance immunosuppression plus placebo (saline) as defined by a composite endpoint of a) CLAD, b) listed for re-transplantation, and c) death

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel Kreisel, M.D.
Washington University School of Medicine
Study Chair
clinicaltrials.gov ↗
Joren Madsen, MD, D.Phil.
Massachusetts General Hospital
Principal Investigator
clinicaltrials.gov ↗
Ramsey Hachem, MD
University of Utah Medical Center
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

St. Joseph'S Hospital and Medical Center (site #: 71192)
Phoenix, Arizona, United States
Recruiting
Cedars Sinai Medical Center (site #: 71146)
Beverly Hills, California, United States
Recruiting
David Geffen School of Medicine at Ucla (site #: 71123)
Los Angeles, California, United States
Recruiting
University of Florida Shands Hospital (site #: 71131)
Gainesville, Florida, United States
Not, yet, recruiting
Emory University (site #: 71103)
Atlanta, Georgia, United States
Recruiting
University of Maryland Medical Center (site #: 71138)
Baltimore, Maryland, United States
Withdrawn
Boston Children'S Hospital and Harvard Medical School (site #: 71001)
Boston, Massachusetts, United States
Withdrawn
Massachusetts General Hospital (site #: 71107)
Boston, Massachusetts, United States
Recruiting
Mayo Clinic Rochester (site #: 71160)
Rochester, Minnesota, United States
Not, yet, recruiting
Barnes Jewish Hospital/ Washington University Som (site #: 71191)
St Louis, Missouri, United States
Recruiting
St. Louis Children'S Hospital of Washington University (site #: 71006)
St Louis, Missouri, United States
Withdrawn
Columbia University Medical Center (site #: 71113)
New York, New York, United States
Recruiting
Duke University Medical Center (site #: 71139)
Durham, North Carolina, United States
Recruiting
Cleveland Clinic (site #: 71101)
Cleveland, Ohio, United States
Recruiting
Ohio State University Medical Center (site #: 71196)
Columbus, Ohio, United States
Recruiting
Temple University (site #: 71197)
Philadelphia, Pennsylvania, United States
Not, yet, recruiting
Vanderbilt University (site #: 71174)
Nashville, Tennessee, United States
Recruiting
University of Texas Southwestern (site #: 71187)
Dallas, Texas, United States
Recruiting
Houston Methodist Hospital (site #: 71120)
Houston, Texas, United States
Withdrawn
University of Texas Health Science at San Antonio (site #: 71198)
San Antonio, Texas, United States
Not, yet, recruiting
University of Utah Medical Center (site #: 71126)
Salt Lake City, Utah, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Placebo for TocilizumabTocilizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Feb 2024
Primary completion: 8 Jan 2029
Completion: 8 Jan 2029
Last update posted: 10 Aug 2026
Registered enrollment: 350
Registry id: NCT06033196

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.